[ad_1]
The first-ever HIV viral load test at the treatment site was pre-approved by the World Health Organization (WHO).
The world's first viral load diagnostic test, m-PIMA, has received pre-qualification approval (PQ from WHO). This follows the CE mark received in December 2018. It was developed by Abott.
"m-PIMA HIV-1/2 VL is the only truly portable, point-of-care test specifically designed for use in resource-limited settings, such as in sub-Saharan Africa," said Damian Halloran, Vice President, Infectious Diseases. – Emerging Markets, Rapid Diagnostics, Abbott.
The use of m-Pima should facilitate viral load testing, especially in areas where access to test equipment would be long.
Halloran said: "With the WHO PQ, global funders and ministries of health can now confidently expand access to viral load testing, reaching more people who need it. , with the most compact and most effective HIV diagnostic platform available in the world today.
In order to provide the most effective treatment and care for HIV, WHO recommends that anyone receiving antiretroviral therapy (ART) be tested for viral load at 6 months and at 12 months, and then every year if nobody is stable under ART.
The viral load test is the reference method for monitoring antiretroviral treatment failures. Unfortunately, very few people living in resource-limited countries, such as some countries in sub-Saharan Africa, Asia, and Latin America, have access to the level of care required.
The platform is portable and can be brought to the most remote locations. It is easy to use, deployable at the treatment site and designed to measure viral load in less than 70 minutes when the patient is still present.
This allows people to receive results during the same visit and immediate treatment decisions, reducing the number of people lost to follow-up.
The rapidity of the test is particularly useful for monitoring the viral load of HIV-positive pregnant women and for suspected HIV treatment failure.
M-PIMA HIV-1/2 VL is part of Abbott's comprehensive portfolio of diagnostic solutions for the detection, monitoring and management of HIV viral load.
From the main laboratory to the point of care, Abbott provides essential tools to help healthcare providers make informed decisions about treating people living with HIV.
WHO Prequalification (PQ) aims to ensure that diagnoses, drugs, vaccines and immunization-related equipment and devices for high-burden diseases meet the global standards of quality, safety and health. effectiveness, to optimize the use of health resources and improve health outcomes.
Sign up to advertise your products and services on our Digger.co.ke clbadifieds site and enjoy a free month subscription and 3 free ads in the Standard newspaper.
Related Topics
HIV-PIMAWorld Health Organization Screening Kit
[ad_2]
Source link
